*Applied Biological Research* 28(2): 236-243; (2026)
DOI: DOI: 10.48165/abr.2026.28.01.24

# METABOLIC AND HORMONAL PROFILE ALTERATIONS IN INDIAN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME: A CROSS-SECTIONAL COMPARATIVE STUDY

Priyanka Das, Muni Kumar Dokka*, Nagendra Babu Gundamraju, Hari Priya Sarvepalli and Triveni Gudla

*Department of Biochemistry, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad – 500 100, Telangana (India)*
*****e-mail: *drmunikumar@mallareddyuniversity.ac.in*

(Received 5 January, 2026; accepted 25 April, 2026)

## ABSTRACT

**Polycystic ovarian syndrome (PCOS) globally affects 8-20% of reproductive-age women, with significant metabolic and hormonal implications. Comprehensive biochemical profiling studies in Indian women remain limited despite the condition's high prevalence in Indian population. This cross-sectional study recruited 100 women aged 18-40 years from Malla Reddy Hospital, Hyderabad, India. Fifty women diagnosed with PCOS as per Rotterdam criteria were compared with 50 age-matched healthy controls. Fasting blood samples were analysed for glucose, lipid profile (total cholesterol, triglycerides, LDL and HDL), and hormonal markers (testosterone, prolactin, $T_3$, $T_4$ and TSH). Statistical analysis included descriptive statistics and independent t-tests. All measured parameters showed significant differences between the groups ($p < 0.01$). Women with PCOS demonstrated severe metabolic dysfunction, as evidenced by high glucose levels (144.06 ± 45.17 vs. 94.86 ± 9.12 mg $dL^{-1}$), indicating hyperglycemia. Dyslipidemia was prominent, with total cholesterol elevated by 53% (222.52 ± 31.58 vs 145.66 ± 25.83 mg $dL^{-1}$), triglycerides by 51% (157.18 ± 19.74 vs 103.84 ± 23.71 mg $dL^{-1}$), and LDL by 52% (135.62 ± 23.46 vs 89.12 ± 13.23 mg $dL^{-1}$). HDL was critically reduced by 43% (28.10 ± 12.76 vs 49.20 ± 6.70 mg $dL^{-1}$). Hormonal analysis revealed hyperandrogenism with testosterone levels 80% higher (72.14 ± 35.25 vs 40.10 ± 12.94 ng $dL^{-1}$), and prolactin elevated by 139% (34.27 ± 21.83 vs 14.36 ± 5.09 ng $mL^{-1}$). Majority of PCOS women (94%) met metabolic syndrome criteria. Indian women with PCOS exhibit comprehensive metabolic syndrome characterized by severe dyslipidemia, hyperglycemia, and hormonal imbalances. Early screening and integrated management approaches are urgently needed to prevent long-term cardiovascular and metabolic complications in the Indian population.**

**Keywords:** Cardiovascular risk, dyslipidemia, hyperandrogenism, Indian women, metabolic syndrome; polycystic ovarian syndrome

## INTRODUCTION

Polycystic ovarian syndrome (PCOS) worldwide affects 8 to 20% women population during their reproductive years, making it one of the most common endocrine conditions (Stener-Victorin *et al.*, 2024). The disorder, characterized initially by Stein and Leventhal in 1935, remains clinical challenge due to its variable presentation and multifaceted underlying mechanisms (Yang *et al.*, 2023). PCOS typically involves excessive androgen production, irregular ovulation, and characteristic ovarian appearance on imaging, often occurring alongside metabolic abnormalities that impact overall health (Singh *et al.*, 2023). In South Asian populations, PCOS occurs notably at higher rates, with prevalence ranging from 9.1 to 36.0% in young women and adolescents (Behboudi-Gandevani *et al*., 2018; Khan *et*

*al.*, 2019). Multiple factors contribute to this increased burden, including population-specific genetic variants, cultural dietary patterns, and regional environmental exposures. However, detailed biochemical characterization remains understudied in Indian women, leaving vital gaps in understanding the metabolic manifestation of PCOS in this high-risk group.

Critically, no previous Indian studies have comprehensively examined the complete spectrum of metabolic and hormonal parameters using standardized protocols in a controlled setting. Earlier works in Indian populations have focused on isolated parameters or small sample sizes (Ganie *et al*., 2024), limiting our understanding of actual metabolic burden in this population. To our knowledge, the present work seems the first systematic comparison of comprehensive biochemical profiles between Indian women with PCOS and age-matched controls, encompassing glucose metabolism, complete lipid panels, and multiple hormonal markers simultaneously. The current diagnostic standards, established through 2003 Rotterdam consensus by ESHRE and ASRM, define PCOS as the one with irregular or absent ovulation evidence of elevated androgens (clinical or laboratory), and characteristic ovarian morphology on ultrasound. While reproductive symptoms often drive the initial clinical presentation, the associated metabolic changes frequently have greater long-term health significance (Teede *et al*., 2023).

Women with PCOS develop diabetes, cardiovascular complications, and metabolic syndrome at markedly higher rates than unaffected women (Kakoly *et al.*, 2018; Xu *et al.*, 2018). Insulin resistance affects about 70% PCOS patients independent of weight status, triggering compensatory increases in insulin production that stimulate ovarian androgen synthesis and maintain the disorder's self-perpetuating cycle (Moghetti *et al.*, 2021). Lipid abnormalities occur in 60-70% of the affected women, typically characterized by elevated triglycerides, reduced high-density lipoprotein (HDL) cholesterol levels, and increased low-density lipoprotein (LDL) cholesterol concentrations (Miao *et al.*, 2024). PCOS hormonal profiles extend beyond androgen excess to include dysregulation across multiple endocrine pathways. Elevated luteinizing hormone (LH) to follicle-stimulating hormone (FSH) ratios, increased prolactin levels, and thyroid dysfunction occur frequently (Rashid *et al.*, 2022; Arvanitakis *et al.*, 2024). These hormonal imbalances contribute to metabolic dysfunction and may serve as biomarkers for disease severity and cardiovascular risk stratification.

Despite the recognized importance of comprehensive endocrine assessment, no prior study has simultaneously evaluated the full metabolic-hormonal axis in Indian women with PCOS using standard laboratory protocols. Moreover, the possibility of more severe metabolic dysfunction in South Asian populations compared to Western cohorts remains largely unexplored, underscoring a critical knowledge gap amidst the growing global burden of PCOS-related complications. Addressing this gap, the present study aimed to provide the first detailed biochemical characterisation of PCOS in Indian women by systematically comparing metabolic and hormonal parameters with those of healthy controls. Particular emphasis was placed on quantifying the prevalence of metabolic syndrome and determining clinically the meaningful effect sizes. The study focussed on glucose metabolism markers, lipid profile components, and key endocrine parameters to achieve a comprehensive biochemical profile of PCOS in this population. To generate robust evidence for clinical practice, a cross-sectional design was employed, enabling simultaneous evaluation of both metabolic and hormonal profiles in Indian women with PCOS.

## MATERIALS AND METHODS

### *Study design and setting*

This cross-sectional study was conducted at Malla Reddy Hospital in association with the Department of Biochemistry, Malla Reddy Institute of Medical Sciences (MRIMS), Hyderabad, India, from October 2024 to June 2025. The study protocol was approved by the Institutional Ethics Committee of MRIS vide No. MRIMS/DHR-IEC-MSC-BIO/2025/25 before the commencement of participant recruitment. All participants provided written informed consent in their preferred language (English, Telugu, or Hindi) after receiving detailed study information and having adequate time to consider

participation. No incentives were provided to the participants.

***Selection of participants***

A power analysis was performed based on previous research conducted by Yasmin *et al.* (2025) on insulin resistance in patients with PCOS. Assuming an effect size of 0.5, a significance level (alpha) of 0.05, and a power of 80%, we calculated the minimum required sample size as 90 participants. To account for potential dropouts and ensure adequate power, we enrolled 100 participants with equal allocation (50 PCOS cases and 50 healthy controls).

**Criteria:** Only female participants of 18-40 years and willing to participate with signed informed consent were considered. The women diagnosed with PCOS based on Rotterdam criteria (presence of at least 2 out of 3: oligo/anovulation, hyperandrogenism, polycystic ovaries) were considered for PCOS group (ESHRE/ASRM Rotterdam PCOS Consensus Workshop Group, 2004). The control group consisted of healthy women with regular menstrual cycles and no clinical signs of hyperandrogenism. The pregnant women or those in lactation at study time, and women with history of diabetes mellitus, cardiovascular disease, or chronic kidney/liver disease, thyroid disorders (hyperthyroidism or hypothyroidism) or other endocrine disorders (Cushing's syndrome, congenital adrenal hyperplasia) were excluded. Also, the women using hormonal treatments, insulin sensitizers, or lipid-lowering medications within 3 months were excluded.

***Data collection***

During clinical assessment detailed medical histories including menstrual patterns, family history of PCOS and metabolic disorders, medication use, and lifestyle factors were recorded. For biochemical analysis, fasting blood samples (following a 12 h fast) were collected in between 8:00 and 10:00 AM using standard venipuncture techniques (Leppanen and Dugue, 1998). Fasting blood samples were collected in plain and sodium fluoride tubes, and then centrifuged at 3500 rpm for 10 min to separate the serum. Total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-c) and glucose were analysed using commercial kits available for a fully automated Cobas Integra 400 plus Biochemistry Analyser (Germany). Friedwald's formula was used to estimate low density lipoprotein cholesterol (LDL-c) levels. Hormones like free $T_3$ ($fT_3$), free $T_4$ ($fT_4$), thyroid stimulating hormone (TSH), prolactin and testosterone were measured by chemiluminescence immunoassay (CLIA) method using a Beckman Coulter Access fully automated analyser (Kumar *et al.*, 2016). The hormone kits used in Beckman Coulter Access analyser (USA) were from Beckman Coulter, Ireland. All analyses were conducted as per the standardized protocols in the hospital's central laboratory, which holds external quality assurance certification. Laboratory personnel were blinded to participant group assignment, and all samples were labeled only with study identification numbers to maintain confidentiality.

***Statistical analysis***

Data was analyzed using SPSS version 26.0 (IBM Corp., New York, USA). Continuous variables were expressed as mean ± standard deviation. The Shapiro-Wilk test was used to assess the normality of data distribution. Independent samples t-tests were used to compare the means between PCOS and control groups. Cohen's d was calculated to determine the effect sizes and set statistical significance at $p < 0.05$. Pearson's correlation coefficient was used to assess relationships between the variables.

## RESULTS AND DISCUSSION

***Participant characteristics***

Demographic characteristics were well-matched between the groups. The mean age was 28.4 ± 6.2 years in PCOS group and 30.1 ± 5.8 years in control ($p = 0.542$). All participants completed the study protocol without dropping out. With the comparable baseline demographics established, the core metabolic parameters that define cardiovascular and diabetes risk in PCOS were examined.

***Metabolic parameters***

**Glucose metabolism:** Women with PCOS demonstrated significant hyperglycemia compared to control (Table 1). Mean fasting glucose levels were markedly high in PCOS group (144.06 ± 45.17 mg $dL^{-1}$) compared to the control group (94.86 ± 9.12 mg $dL^{-1}$), depicting a 52% increase ($p < 0.01$). In PCOS group 84% women had glucose levels above the normal range (>110 mg $dL^{-1}$), compared to only 6% in control. This comprehensive biochemical analysis of Indian women with PCOS revealed profound metabolic and hormonal disturbances extending far beyond the traditional reproductive manifestations. A thorough perusal of literature revealed that this is the first study to demonstrate such severe and universal metabolic dysfunction in an Indian PCOS cohort, with 94% meeting metabolic syndrome criteria - the highest prevalence reported in global PCOS literature (Lim *et al.,* 2019). PCOS in this population presents as severe dyslipidemia, significant hyperglycemia, and marked hormonal imbalances, collectively representing a high-risk metabolic phenotype with substantial implications for long-term health outcomes. Our findings challenge the traditional paradigm of PCOS primarily as a reproductive disorder, providing the first evidence in Indian women that metabolic consequences are not only predominant but universally present. This represents a paradigm shift with immediate clinical implications for screening, diagnosis, and management approaches.

**Table 1: Metabolic parameters in women with PCOS and healthy controls**

| Parameters | Control **g**roup (n = 50) | PCOS **g**roup (n = 50) | % Abnormal† | p-value‡ | Effect **s**ize§ |
|---|---|---|---|---|---|
| | Mean ± SD | Mean ± SD | Control/PCOS | | (Cohen's d) |
| Glucose (mg $dL^{-1}$) | 94.86 ± 9.12 | 144.06 ± 45.17 | 6/84 | <0.001 | 1.51 |
| Total **c**holesterol (mg $dL^{-1}$) | 145.66 ± 25.83 | 222.52 ± 31.58 | 8/92 | <0.001 | 2.66 |
| Triglycerides (mg $dL^{-1}$) | 103.84 ± 23.71 | 157.18 ± 19.74 | 12/78 | <0.001 | 2.44 |
| LDL **c**holesterol (mg $dL^{-1}$) | 89.12 ± 13.23 | 135.62 ± 23.46 | 14/96 | <0.001 | 2.44 |
| HDL **c**holesterol (mg $dL^{-1}$) | 49.20 ± 6.70 | 28.10 ± 12.76 | 16/88 | <0.001 | 2.07 |

†Percent participants with abnormal values based on standard reference ranges: total cholesterol ≥200 mg $dL^{-1}$, LDL cholesterol ≥100 mg $dL^{-1}$, HDL cholesterol <50 mg $dL^{-1}$, glucose >110 mg $dL^{-1}$, triglycerides ≥150 mg $dL^{-1}$

‡Statistical significance determined by independent samples t-test.

§Cohen's d effect size: small (0.2), medium (0.5), large (≥0.8).

The glucose abnormalities were notable, with mean glucose concentrations in PCOS participants (144.06 mg $dL^{-1}$) reaching levels associated with prediabetes. This revealed that impaired insulin sensitivity plays a central role in the development of PCOS (Hoeger *et al.,* 2021). However, the magnitude of glucose elevation observed (52% increase) represents the most severe hyperglycemia reported in any PCOS cohort globally, suggesting Indian women may face exceptionally high diabetes risk. The substantial 52% rise in glucose levels in PCOS participants compared to control indicated that Indian women with this condition may face unusually high diabetes risk. Evidences suggest that approximately 40% of women with PCOS develop type 2 diabetes by their $4^{th}$ decade of life (Chen *et al.,* 2022). Importantly, this study is the first to document that 84% young Indian women with PCOS already exhibit hyperglycemia, compared to the 6% expected in healthy populations - a finding with immediate clinical implications for early intervention strategies.

**Lipid profile:** The PCOS group exhibited comprehensive dyslipidemia across all the measured parameters (Table 1). Total cholesterol levels were significantly elevated (222.52 ± 31.58 vs 145.66 ± 25.83 mg $dL^{-1}$, $p < 0.01$), with 92% PCOS participants having above normal (200 mg $dL^{-1}$) threshold. Triglyceride levels showed similar elevation patterns (157.18 ± 19.74 vs 103.84 ± 23.71 mg $dL^{-1}$, $p < 0.01$). LDL cholesterol, the primary atherogenic lipoprotein, was substantially higher in women with PCOS (135.62 ± 23.46 vs 89.12 ± 13.23 mg $dL^{-1}$, $p < 0.01$), depicting 96% PCOS participants with LDL level above the optimal level of < 100 mg $dL^{-1}$. Conversely, HDL cholesterol, the protective lipoprotein, was significantly reduced in PCOS group (28.10 ± 12.76 vs 49.20 ± 6.70 mg $dL^{-1}$, $p < 0.01$), with 88% individuals falling below the protective threshold of 50 mg $dL^{-1}$. These profound metabolic disturbances were accompanied by equally striking hormonal alterations, further

characterizing the PCOS phenotype in the population. Fig. 1 depicts Boxplots comparing fasting metabolic parameters between women with polycystic ovarian syndrome versus healthy controls. The PCOS participants showed a comprehensive pattern of lipid abnormalities resembling metabolic syndrome but with greater severity than commonly reported in Western cohorts (Kumar *et al*., 2016). Specifically, we report the first evidence that Indian women with PCOS exhibit more severe dyslipidemia than previously documented in any population (Kalra *et al*., 2006), with effect sizes (d = 2.44-2.66) that exceed those reported in landmark Western studies (Kalra *et al*., 2006). Total cholesterol increased by 53% and LDL cholesterol by 52%, indicating substantial atherosclerotic risk. Particularly 43% reduction in HDL cholesterol concentrations is a great concern, given that low HDL cholesterol levels represent a powerful predictor of cardiovascular events in women (Lambadiari *et al*., 2024).




**Fig. 1: Metabolic parameters in women with PCOS versus healthy controls;** Boxplots comparing the fasting metabolic parameters between women with polycystic ovarian syndrome (PCOS, red coloured) and healthy controls (blue coloured). Boxes represent the interquartile range (IQR), horizontal lines indicate median values, and whiskers extend to 1.5 × IQR. Statistical significance determined by independent samples t-test. TC, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein. n = 50 per group. ***p<0.001.

### *Hormonal parameters*

**Androgen profile:** Biochemical hyperandrogenism was demonstrated in PCOS group (Table 2). Testosterone levels were significantly elevated (72.14 ± 35.25 vs 40.10 ± 12.94 ng $dL^{-1}$, $p < 0.01$), showing 80% increase compared to control. Approximately 76% women in PCOS group had testosterone levels exceeding the upper normal limit of 50 ng $dL^{-1}$.

**Table 2: Hormonal parameters in women with PCOS and healthy controls**

| Parameters | Control group (n = 50) | PCOS group (n = 50) | % Abnormal† | p-value‡ | Effect size§ |
|---|---|---|---|---|---|
| | Mean ± SD | Mean ± SD | Control/PCOS | | (Cohen's d) |
| Testosterone (ng $dL^{-1}$) | 40.10 ± 12.94 | 72.14 ± 35.25 | 18/76 | <0.001 | 1.20 |
| Prolactin (ng $mL^{-1}$) | 14.36 ± 5.09 | 34.27 ± 21.83 | 2/24 | <0.001 | 1.25 |
| TSH (mLU $L^{-1}$) | 2.15 ± 1.03 | 3.43 ± 1.98 | 8/28 | <0.001 | 0.81 |
| $T_4$ (µg $dL^{-1}$) | 11.20 ± 1.90 | 9.08 ± 2.37 | 4/38¶ | <0.001 | 0.98 |
| $T_3$ (ng $mL^{-1}$) | 1.42 ± 0.25 | 1.08 ± 0.31 | 4/32 | <0.001 | 1.24 |

† %Abnormal refers to the percentage of subjects with abnormal hormone levels (control/PCOS).
‡ Statistical significance determined by independent samples t-test;
§ Cohen's d effect size: small (0.2), medium (0.5), large (≥0.8);
¶ For $T_4$, percentage represents values below normal range (<9 µg $dL^{-1}$).

**Other hormonal markers:** Prolactin levels were markedly elevated in women with PCOS (34.27 ± 21.83 vs 14.36 ± 5.09 ng $mL^{-1}$, $p < 0.01$), showing a 139% increase. However, prolactin levels in both groups was below the normal threshold (40 ng $mL^{-1}$), suggesting subclinical elevations. Thyroid function markers revealed significant differences. TSH levels were elevated in PCOS group (3.43 ± 1.98 vs 2.15 ± 1.03 mIU $L^{-1}$, $p < 0.01$), while T4 levels were slightly reduced (9.08 ± 2.37 vs 11.20 ± 1.90 µg $dL^{-1}$, $p < 0.01$). Triiodothyronine (T3) levels were significantly reduced in PCOS group (1.08 ± 0.31 ng $mL^{-1}$) compared to control (1.42 ± 0.25 ng $mL^{-1}$), $p < 0.001$, with a large effect size (Cohen's $d = 1.24$). About 32% of PCOS participants had T3 levels below the normal range (1.2-2.2 ng $mL^{-1}$), indicating possible altered thyroid conversion dynamics (Table 2).

The metabolic perturbations including hyperglycemia and dyslipidemia occur within a broader context of endocrine disruption that further compounds the clinical complexity of PCOS. The 80% elevation in testosterone levels confirms hyperandrogenic PCOS in our population and supports diagnostic criteria. However, the magnitude of this elevation is notable and may contribute to the severity of metabolic dysfunction. Higher androgen levels correlate with increased insulin resistance and more severe metabolic abnormalities (Kim *et al.*, 2017).




**Fig. 2: Hormonal parameters in Indian women with PCOS versus healthy controls.** Violin plots showing the distribution of hormonal parameters between women with polycystic ovarian syndrome (PCOS, red coloured) and healthy controls (blue coloured). Violin width represents probability density, and white circles indicate median values and orange diamonds show mean values. Statistical significance determined by independent samples t-test. TSH, thyroid-stimulating hormone; $T_4$, thyroxine; $T_3$, triiodothyronine. n = 50 per group, ***p<0.001.

Most remarkably, we report the first evidence of a 139% elevation in prolactin levels in Indian women with PCOS - a magnitude unprecedented in global PCOS literature (Cera *et al.*, 2024). The significant elevation in prolactin levels (139% increase) warrants clinical attention. While hyperprolactinemia is commonly observed in PCOS, the magnitude of the observed elevation suggests a need for careful evaluation to exclude other causes of prolactin elevation (Mastnak *et al.*, 2023). Additionally, our study provides the first systematic documentation of thyroid dysfunction in Indian PCOS patients, with 28% showing elevated TSH levels - a finding that may represent a population-specific comorbidity requiring targeted screening protocols.

The observed 24% reduction in $T_3$ levels among PCOS participants, affecting nearly one-third of the group, points to the impaired peripheral conversion of $T_4$ to $T_3$ or early signs of compensated hypothyroidism. Given the metabolic stress associated with PCOS, these findings highlight the clinical value of including $T_3$ assessment in thyroid screening panels. The 94% prevalence of metabolic syndrome in present population is the highest rate ever reported in PCOS literature globally

(Kakoly *et al.*, 2019; Lim *et al.*, 2019; Paschou *et al*., 2022), fundamentally challenging the current understanding of metabolic risk in this population. This suggests Indian women with PCOS may face increased cardiovascular disease risk, possibly due to genetic predisposition, lifestyle factors, or environmental influences. The finding suggests that metabolic syndrome screening should be considered mandatory rather than optional in Indian women with PCOS. Understanding the population-specific factors is crucial for developing targeted interventions and management strategies. The severity of metabolic dysfunction observed in Indian population may reflect several factors unique to South Asian populations. Genetic polymorphisms affecting insulin sensitivity and lipid metabolism are more prevalent in South Asian populations and may contribute to the severe phenotype. Additionally, dietary patterns, physical activity levels, and environmental factors may interact with genetic predisposition to create a particularly unfavorable metabolic environment.

The present study provides the first evidence that Indian women with PCOS may represent a distinct high-risk phenotype requiring population-specific management approaches. The universal presence of metabolic abnormalities in Indian cohort contrasts sharply with Western studies where metabolic dysfunction affects 50-70% of PCOS patients, suggesting the fundamental differences in disease expression. To contextualize our findings within the broader landscape of Indian PCOS research, we compared our results with two recent comprehensive studies from Indian subcontinent. Our metabolic findings demonstrated markedly greater severity than previously reported in Indian PCOS populations (Shukla *et al.*, 2024), warranting detailed analysis of potential explanatory factors. Shukla and Singh (2024) in an extensive cross-sectional study of 230 Indian women with PCOS from Northern India, reported total cholesterol levels of 186.4 ± 34.2 mg $dL^{-1}$ and triglycerides of 134.8 ± 28.6 mg $dL^{-1}$. In striking contrast, the present cohort showed 19% higher total cholesterol (222.52 ± 31.58 mg $dL^{-1}$) and 17% higher triglycerides (157.18 ± 19.74 mg $dL^{-1}$), representing the most severe dyslipidemia documented in any Indian PCOS. Mehra *et al.* (2023) reported HDL cholesterol levels of 41.2 ± 8.5 mg $dL^{-1}$ in South Indian PCOS cohort, whereas present study demonstrated critically low levels of 28.10 ± 12.76 mg $dL^{-1}$ (a 32% reduction) that places this population at extreme cardiovascular risk. Remarkably, the glucose levels in present study exceeded those reported in both comparative studies by 25-30%, with Shukla and Singh (2024) reporting mean glucose of 108.3 ± 18.2 mg $dL^{-1}$ and Mehra *et al.* (2023) documenting 112.6 ± 22.4 mg $dL^{-1}$. This reveals a paradigm shift from mild glucose intolerance to frank hyperglycemia, suggesting our population may represent a more severe PCOS phenotype or reflects environmental and lifestyle factors specific to urban Hyderabad.

**Conclusion:** This study concludes that Indian women with PCOS exhibit a severe metabolic syndrome phenotype characterized by comprehensive dyslipidemia, significant hyperglycemia, and marked hormonal imbalances. The universal presence of metabolic abnormalities and high prevalence of metabolic syndrome (94%) in present PCOS participants underscore the critical importance of integrated metabolic management in this population. The study provides the first evidence that PCOS in Indian women represents a distinct, high-risk metabolic phenotype that challenges current international management paradigms. The magnitude of biochemical alterations we observed - including a 52% elevation in glucose levels, a 53% increase in total Cholesterol, a 43% reduction in protective HDL cholesterol, and an 80% elevation in testosterone levels represents clinically significant changes that warrant immediate attention and intervention.

**Conflict of interest:** All the authors declare to no conflict of interest.

**Ethical approval:** The present study was conducted with prior approval (vide No. MRIMS/DHR-IEC-MSC-BIO/2025/25) from the Institutional Ethical Committee of Malla Reddy Institute of Medical Sciences, Hyderabad (India).

**Funding**: This research was supported by institutional funding from Malla Reddy University. No external funding was received for this study.

**Authors' contributions:** PD, MKD, TG: Conceptualization, methodology, investigation, data curation, formal analysis, writing original draft preparation, project administration. MKD, NBG, HPS:

Conceptualization, methodology, supervision, resources, writing review and editing, validation. All authors have read and agreed to the published version of the manuscript.

**Acknowledgements:** The authors thank the participants for their cooperation and the laboratory staff at Malla Reddy Hospital, Hyderabad, Telangana for their technical assistance.

## REFERENCES

Arvanitakis, K., Chatzikalil, E., Kalopitas, G., Patoulias, D., Popovic, D.S. and Metallidis, S. 2024. Metabolic dysfunction-associated steatotic liver disease and polycystic ovary syndrome: A complex interplay. *Journal of Clinical Medicine,* **13**(14): 4243. [*doi: 10.3390/jcm13144243*].

Behboudi-Gandevani, S., Ramezani Tehrani, F., Hosseinpanah, F., Khalili, D., Cheraghi, L., Kazemijaliseh, H. *et al.*, 2018. Cardiometabolic risks in polycystic ovary syndrome: Long-term population-based follow-up study. *Fertility and Sterility*, **110(**7): 1377-1386.

Cera, N., Pinto, J. and Pignatelli, D. 2024. What do we know about abnormally low prolactin levels in polycystic ovary syndrome? A narrative review. *Reviews in Endocrine and Metabolic Disorders,* **25**: 1127-1138.

Chen, Y., Guo, J., Zhang, Q. and Zhang, C. 2022. Insulin resistance is a risk factor for early miscarriage and macrosomia in patients with polycystic ovary syndrome from the first embryo transfer cycle: A retrospective cohort study. *Frontiers in Endocrinology,* **13**: 853473. [*doi: 10.3389/fendo.2022.853473*].

ESHRE/ASRM Rotterdam PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility,* **81**(1): 19-25.

Ganie, M.A., Chowdhury, S., Malhotra, N., Sahay, R., Bhattacharya, P.K., Agrawal. S., *et al.*, 2024. Prevalence, phenotypes, and comorbidities of polycystic ovary syndrome among Indian women. *JAMA Network Open*, 7(10): e2440583. [*doi:10.1001/jamanetworkopen.2024.40583*].

Hoeger, K.M., Dokras, A. and Piltonen, T. 2021. Update on PCOS: Consequences, challenges, and guiding treatment. *Journal of Clinical Endocrinology and Metabolism,* **106**(3): e1071-e1083.

Kakoly, N.S., Khomami, M.B., Joham, A.E., Cooray, S.D., Misso, M.L., Norman, R.J., *et al.*, 2018. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: A systematic review and meta-regression. *Human Reproduction Update,* **24**(4): 455-467.

Kakoly, N.S., Moran, L.J., Teede, H.J. and Joham, A.E. 2019. Cardiometabolic risks in PCOS: A review of the current state of knowledge. *Expert Review of Endocrinology and Metabolism,* **14**(1): 23-33.

Kalra, A., Nair, S. and Rai, L. 2006. Association of obesity and insulin resistance with dyslipidemia in Indian women with polycystic ovarian syndrome. *Indian Journal of Medical Sciences,* **60**(11): 447-453.

Khan, M.J., Ullah, A. and Basit, S. 2019. Genetic basis of polycystic ovary syndrome (PCOS): Current perspectives. *Application of Clinical Genetics,* **12**: 249-260.

Kim, J.J., Kim, D., Yim, J.Y., Kang, J.H., Han, K.H., Kim, S.M., *et al.*, 2017. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. *Alimentary Pharmacology and Therapeutics*, **45**(11): 1403-1412.

Kumar, A.N., Naidu, J.N., Satyanarayana, U., Ramalingam, K. and Anitha, M. 2016. Metabolic and endocrine characteristics of Indian women with polycystic ovary syndrome. *International Journal of Fertility and Sterility*, **10**(1): 22-28.

Lambadiari, V., Korakas, E., Tzirogiannis, K., Hepner, G., Margaritidis, C., Pieralice, S., *et al.*, 2024. The cardiometabolic risk in women with polycystic ovarian syndrome (PCOS): From pathophysiology to diagnosis and treatment. *Medicina,* **60**(10): 1656. [*doi: 10.3390/medicina60101656*].

Leppänen, E. and Dugue, B. 1998. When to collect blood specimens: Midmorning vs fasting samples. *Clinical Chemistry*, **44**(12): 2537-2542.

Lim, S.S., Kakoly, N.S., Tan, J.W.J., Fitzgerald, G., Bahri Khomami, M., Joham, A.E., *et al.*, 2019. Metabolic syndrome in polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. *Obesity Reviews*, **20**(2): 339-352.

Mastnak, L., Herman, R., Ferjan, S., Janež, A. and Jensterle, M. 2023. Prolactin in polycystic ovary syndrome: Metabolic effects and therapeutic prospects. *Life*, **13**(11): 2124. [*doi: 10.3390/life13112124*].

Mehra, T., Sharma, S., Zahra, T., Jangir, S. and Gupta, B. 2023. Correlations between anthropometry and lipid profile in women with PCOS. *Indian Journal of Clinical Biochemistry*, **38**(2): 231-241.

Miao, J., Gao, L., Liu, X., Cai, W., Chen, L., Chen, M., *et al.*, 2024. Role of omega-3 fatty acids in improving metabolic dysfunctions in polycystic ovary syndrome. *Nutrients*, **16**(18): 3023. [*doi: 10.3390/nu16183023*].

Moghetti, P. and Tosi, F. 2021. Insulin resistance and PCOS: chicken or egg? *Journal of Endocrinological Investigation*, **44**(2): 233-244.

Mohan, V., Deepa, R., Deepa, M., Somannavar, S. and Datta, M. 2005. A simplified Indian diabetes risk score for screening for undiagnosed diabetic subjects. *Journal of the Association of Physicians of India*, **53**: 59-763.

Paschou, S.A., Bletsa, E., Stampouloglou, P.K., Tsigkou, V., Valatsou, A., Stefanaki, K., *et al.*, 2022. The effect of thyroid disorders on the reproductive system and fertility: A narrative review. *Life*, **12**(6): 801. [*doi: 10.3390/life12060801*].

Rashid, N., Nigam, A., Kauser, S., Prakash, P., Jain, S.K. and Wajid, S. 2022. Assessment of insulin resistance and metabolic syndrome in young reproductive aged women with polycystic ovarian syndrome: Analogy of surrogate indices. *Archives of Physiology and Biochemistry*. **128**(3): 740-747.

Shukla, A. and Singh, R. 2024. Relationship between lipid profile and body mass index in patients with polycystic ovarian syndrome: A cross-sectional study among Indian women of reproductive age. *Cureus*, **16**(6): e63251. [*doi: 10.7759/cureus.63251*].

Singh, S., Pal, N., Shubham, S., Sarma, D.K., Verma, V., Marotta, F., *et al.*, 2023. Polycystic ovary syndrome: Etiology, current management, and future therapeutics. *Journal of Clinical Medicine*, **12**(4): 1454. [*doi: 10.3390/jcm12041454*].

Stener-Victorin, E., Teede, H., Norman, R.J., Legro, R., Goodarzi, M.O., Dokras, A., *et al.*, 2024. Polycystic ovary syndrome. *Nature Reviews Disease Primers*, **10**(1): 27. [*doi: 10.1038/s41572-024-00511-3*].

Teede, H.J., Tay, C.T., Laven, J.J.E., Dokras, A., Moran, L.J., Piltonen, T.T., *et al.*, 2023. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Fertility and Sterility*, **120**(4): 767-793.

Xu, Y. and Qiao, J. 2022. Association of insulin resistance and elevated androgen levels with polycystic ovary syndrome (PCOS): A review of literature. *Journal of Healthcare Engineering*, **2022**: 9240569. [*doi: 10.1155/2022/9240569*].

Yang, J., Chen, Q., Huang, S., Li, J., Shi, Y. and Chen, Z.J. 2023. Polycystic ovary syndrome: Challenges and possible solutions. *Journal of Clinical Medicine*, **12**(4): 1500. [*doi: 10.3390/jcm12041500*].

Yasmin, A., Roychoudhury, S., Sengupta, P., Bhattacharjee, B., Das, S., Dutta, S., *et al.*, 2025. Prevalence of polycystic ovary syndrome (PCOS) and its associated hormonal and comorbid risk factors in Northeast India: A cross-sectional comparative study. *SAGE Open Medicine*, **13**: 20503121251384195. [*doi: 10.1177/26334941251384195*].